

NUPLAZID DISTRIBUTION FACT SHEET FOR LONG-TERM CARE

Overview ¹	
Product name	NUPLAZID [®] (pimavanserin)
Generic name	Pimavanserin
National drug codes (NDCs)	NUPLAZID 34 mg capsules (bottle of 30): NDC 63090-340-30 NUPLAZID 10 mg tablets (bottle of 30): NDC 63090-100-30
Indication and usage	NUPLAZID is an atypical antipsychotic indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.
Dosage and administration	The recommended dose of NUPLAZID is 34 mg taken orally once daily, without titration. NUPLAZID can be taken with or without food. For those patients who are concomitantly receiving strong CYP3A4 inhibitors, reduce NUPLAZID dose to 10 mg taken orally once daily. Patients who are concomitantly administered strong CYP3A4 inducers should be monitored for reduced efficacy and an increase in dosage may be needed.
Manufacturer	ACADIA Pharmaceuticals Inc.
Distribution	
Specialty distributors	Eligible government, long-term care, and hospital inpatient pharmacies may order NUPLAZID directly from: <ul style="list-style-type: none"> ▪ ASD Healthcare: AmerisourceBergen 1-800-746-6273 ▪ Cardinal Health 1-844-794-7276 ▪ McKesson Plasma and Biologics 1-877-625-2566
Group purchasing organizations	<ul style="list-style-type: none"> ▪ GeriMed 1-800-456-4374 ▪ Innovatix 1-888-258-3273 ▪ MHA 1-800-642-3020
Specialty pharmacy network	<ul style="list-style-type: none"> ▪ Accredo Specialty Pharmacy 1-877-222-7336 ▪ AllianceRx Walgreens Prime 1-888-782-8443 ▪ Diplomat 1-877-977-9118 ▪ Advanced Care Scripts 1-877-985-6337 ▪ CVS Specialty Pharmacy 1-800-237-2767
Price and resident support	
Wholesale acquisition cost	\$2,778.00 for 30-count bottle (1-month supply)
Support program	NUPLAZIDconnect [™] focuses on access, so you can focus on your residents. NUPLAZIDconnect provides patient access support for your residents, including navigating insurance, managing cost, and filling their prescription. <ul style="list-style-type: none"> ▪ NUPLAZIDconnect dedicated LTC support hotline: 1-877-889-0739

Indication

NUPLAZID is an atypical antipsychotic indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

Important Safety Information for NUPLAZID (pimavanserin)

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. NUPLAZID is not approved for the treatment of patients with dementia-related psychosis unrelated to the hallucinations and delusions associated with Parkinson's disease psychosis.

See additional Important Safety Information on back.

Please read the accompanying full Prescribing Information or visit NUPLAZIDhcp.com.

Important Safety Information for NUPLAZID (pimavanserin) (cont'd)

Contraindication: NUPLAZID is contraindicated in patients with a history of a hypersensitivity reaction to pimavanserin or any of its components. Rash, urticaria, and reactions consistent with angioedema (e.g., tongue swelling, circumoral edema, throat tightness, and dyspnea) have been reported.

QT Interval Prolongation: NUPLAZID prolongs the QT interval. The use of NUPLAZID should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong QT interval including Class 1A antiarrhythmics or Class 3 antiarrhythmics, certain antipsychotic medications, and certain antibiotics. NUPLAZID should also be avoided in patients with a history of cardiac arrhythmias, as well as other circumstances that may increase the risk of the occurrence of torsade de pointes and/or sudden death, including symptomatic bradycardia, hypokalemia or hypomagnesemia, and presence of congenital prolongation of the QT interval.

Adverse Reactions: The most common adverse reactions ($\geq 2\%$ for NUPLAZID and greater than placebo) were peripheral edema (7% vs 2%), nausea (7% vs 4%), confusional state (6% vs 3%), hallucination (5% vs 3%), constipation (4% vs 3%), and gait disturbance (2% vs <1%).

Drug Interactions: Coadministration with strong CYP3A4 inhibitors (e.g., ketoconazole) increases NUPLAZID exposure. Reduce NUPLAZID dose to 10 mg taken orally as one tablet once daily. Coadministration with strong CYP3A4 inducers may reduce NUPLAZID exposure. Monitor patients for reduced efficacy and an increase in NUPLAZID dosage may be needed.

Pediatric Use: Safety and efficacy have not been established in pediatric patients.

Dosage and Administration

Recommended dose: 34 mg taken orally once daily, without titration.

NUPLAZID is available as 34 mg capsules (NDC: 63090-340-30), 17 mg tablets (NDC: 63090-170-60), and 10 mg tablets (NDC: 63090-100-30).

Please read the accompanying full Prescribing Information including **Boxed WARNING** or visit NUPLAZIDhcp.com.

Reference: 1. NUPLAZID® (pimavanserin) prescribing information, ACADIA.



©2018 ACADIA Pharmaceuticals Inc. All rights reserved. NC-0149 07/18.

ONCE-DAILY
NUPLAZID®
(pimavanserin) 34mg capsules